Alendronate for Effective Treatment of Male Osteoporosis : An Insight

被引:0
作者
Al Lawati, Hanan [1 ]
Al Busaidi, Sara [2 ]
Al Rawahi, Thuraiya [3 ]
Al Lawati, Abdullah [4 ]
Kifah, Ahmed [5 ]
Das, Srijit [6 ]
机构
[1] Oman Coll Hlth Sci, Dept Pharmaceut, Pharm Program, Muscat, Oman
[2] Sultan Qaboos Univ, Muscat, Oman
[3] Royal Coll Surg Ireland Bahrain, Muharraq, Bahrain
[4] Sultan Qaboos Univ Hosp, Muscat, Oman
[5] Natl Univ, Sohar, Oman
[6] Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Human & Clin Anat, Muscat, Oman
关键词
Alendronate; drug; osteoporosis; male; skeletal; bone; BONE-MINERAL DENSITY; VERTEBRAL FRACTURE RISK; ZOLEDRONIC ACID; PARATHYROID-HORMONE; DOUBLE-BLIND; IN-VITRO; BISPHOSPHONATES; MEN; WOMEN; PREVALENCE;
D O I
10.2174/0113816128310838240820065324
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Osteoporosis is a major global health problem. The increase in the incidence of osteoporosis in the elderly poses a challenge to treat and also results in an economic burden for the nation. Osteoporosis has been given more importance in females, and there is an urgent need to address this disease in males. Various drugs, such as nitrogen-containing phosphonates, RANK ligand inhibitors, parathormones, and alendronate, have been used for effective treatment of osteoporosis. Alendronate (alendronic acid), a nitrogen-containing bisphosphonate that inhibits bone resorption by osteoclasts, was synthesized during the 1970s. In the present review, we discuss the pharmacokinetics, mechanism of action, adverse effects, contraindications, and toxicity monitoring of alendronate. The drug may be effectively used for the treatment of male osteoporosis in order to increase bone mineral density and prevent fractures.
引用
收藏
页码:26 / 36
页数:11
相关论文
共 141 条
[71]   Renal safety of intravenous bisphosphonates in the treatment of osteoporosis [J].
Lewiecki, E. Michael ;
Miller, Paul D. .
EXPERT OPINION ON DRUG SAFETY, 2007, 6 (06) :663-672
[72]   Bisphosphonates: A review of their pharmacokinetic properties [J].
Lin, JH .
BONE, 1996, 18 (02) :75-85
[73]  
LIN JH, 1991, DRUG METAB DISPOS, V19, P926
[74]   ON THE ABSORPTION OF ALENDRONATE IN RATS [J].
LIN, JH ;
CHEN, IW ;
DELUNA, FA .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 83 (12) :1741-1746
[75]   THE BURDEN OF OSTEOPOROSIS - COST [J].
LINDSAY, R .
AMERICAN JOURNAL OF MEDICINE, 1995, 98 :S9-S11
[76]  
Liu MY, 2015, INT J CLIN EXP MED, V8, P3855
[77]   Trends in osteoporosis and low bone mass in older US adults, 2005-2006 through 2013-2014 [J].
Looker, A. C. ;
Isfahani, N. Sarafrazi ;
Fan, B. ;
Shepherd, J. A. .
OSTEOPOROSIS INTERNATIONAL, 2017, 28 (06) :1979-1988
[78]   Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras [J].
Luckman, SP ;
Hughes, DE ;
Coxon, FP ;
Russell, RGG ;
Rogers, MJ .
JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (04) :581-589
[79]   Rare causes of osteoporosis [J].
Marcucci, Gemma ;
Brandi, Maria Luisa .
CLINICAL CASES IN MINERAL AND BONE METABOLISM, 2015, 12 (02) :151-156